Clinical Trials Update: Nov. 30, 2004
Posted on: Tuesday, 30 November 2004, 12:00 CST
(HealthDayNews) -- Here are the latest clinical trials, courtesy of CenterWatch:
Osteoporosis
A research study evaluating patient satisfaction with a once-monthly pill for the treatment and prevention of osteoporosis. Volunteers who have been taking weekly medication for the prevention of postmenopausal osteoporosis for at least three months may be eligible. Research site located in Clearwater, Fla.
More Information
Please see http://www.centerwatch.com/patient/studies/cat111.html.
-----
Heart Disease
A research study testing whether insulin glargine and omega-3 fatty acids can prevent future cardiovascular disease and associated complications. Volunteers 50 or older who have any of these risk factors may be eligible: a blood-sugar level that is slightly high, type 2 diabetes treated by a maximum of one pill, a previous heart attack or stroke, stable or unstable angina, or other diseases of the heart or blood vessels. Research site located in Los Angeles, Calif.
More Information
Please see http://www.centerwatch.com/patient/studies/cat213.html.
-----
Stomach Discomfort
A research study of an investigational medication for dyspepsia. Volunteers 18 or older who have active dyspepsia symptoms may be eligible to participate in this 9-week study. Research site located in Dallas, TX.
More Information
Please see http://www.centerwatch.com/patient/studies/cat310.html.
-----
Copyright 2004 CenterWatch. All rights reserved.
~CLIN~
Source: HealthSCOUT
Related Articles
- Elsevier Releases Results of Alternative Energy Research Leadership Study Identifying Top 25 Institutions Worldwide
- N-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
- Cytokinetics Announces Positive Results From an Interim Analysis of an Ongoing Phase IIa Clinical Trial of CK-1827452 in Patients With Stable Heart Failure
- MultiVu Video Feed: Intensive Lipitor Therapy Cuts The Risk of Hospitalizations Due to Heart Failure in Patients With Coronary Heart Disease, New Analysis Shows
- Covalent Group, Inc. Signs Contracts Totaling $1.5 Million for Clinical Studies Offering Advanced Therapeutic Approaches to Patients With Severe Heart Failure
- Study Sees More Benefit from Some Heart Drugs
- 8000 Patients Wait More Than Year to See Specialist SNP Criticises 'Appalling Record on Health'
- Pacemakers and Defibrillators for the Survival of Patients Suffering from Heart Insufficiency
- Immunocomb Chlamydia Bivalent Assay to Study Chlamydia Species- Specific Antibodies in Patients With Coronary Heart Disease
- Researchers to Study Apes, Forgiveness
 |
 |
User Comments (0)
RSS Feeds